Liraglutide (Saxenda & Victoza): Complete Guide
Everything you need to know about liraglutide — how it works, dosing, side effects, and how it compares to newer GLP-1 medications like semaglutide and tirzepatide.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on February 21, 2025
Our medical review process ensures clinical accuracy and patient safety.
What is Liraglutide?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for both type 2 diabetes management (Victoza) and chronic weight management (Saxenda). It was one of the first GLP-1 medications to receive FDA approval for weight loss, paving the way for newer agents like semaglutide and tirzepatide.
FDA-Approved Brands
| Brand | Approved Use | Dosing |
|---|---|---|
| Saxenda | Chronic weight management | Daily injection |
| Victoza | Type 2 diabetes | Daily injection |
How Does Liraglutide Work?
Like all GLP-1 receptor agonists, liraglutide mimics the GLP-1 hormone produced in the gut after eating:
- Appetite suppression — signals the hypothalamus to reduce hunger
- Slows gastric emptying — food leaves the stomach more slowly, prolonging fullness
- Stimulates insulin — only when blood glucose is elevated (glucose-dependent)
- Suppresses glucagon — reduces liver glucose output
Liraglutide is a derivative of GLP-1 that shares 97% amino acid sequence homology with its parent molecule[^1]. The drug was created by substituting arginine for lysine at position 34 in the GLP-1 peptide and adding a palmitic acid chain with a glutamic acid spacer on the lysine residue at position 26 to improve pharmacokinetic effects[^1]. Following subcutaneous injection, peak absorption occurs at 11 hours with a half-life of approximately 13 hours, allowing for once-daily administration[^1].
Dosing Schedule (Saxenda)
Liraglutide requires daily subcutaneous injections, unlike weekly semaglutide. This daily dosing schedule is necessitated by its shorter half-life of 13-15 hours compared to semaglutide's 165-hour half-life[^2].
| Week | Dose |
|---|---|
| Week 1 | 0.6 mg/day |
| Week 2 | 1.2 mg/day |
| Week 3 | 1.8 mg/day |
| Week 4 | 2.4 mg/day |
| Week 5+ | 3.0 mg/day (maintenance) |
The dose escalation protocol helps minimize gastrointestinal side effects, which are the most common adverse events during treatment initiation[^1]. If a dose is missed for >72 hours, patients must resume dosing at 0.6 mg daily and restart the titration schedule[^1].
Effectiveness for Weight Loss
In the SCALE Obesity and Prediabetes trial, the landmark 56-week study involving 3,731 participants without type 2 diabetes:
- Average weight loss of 8.4 kg (8.0%) at 56 weeks compared to 2.8 kg (2.6%) with placebo (P<0.001)[^4]
- 63.2% of patients lost ≥5% of body weight (vs 27.1% with placebo)[^4]
- 33.1% lost ≥10% of body weight (vs 10.6% with placebo)[^4]
- Significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, and glycemic control[^4]
Comparison note: Semaglutide (Wegovy) achieves ~15% average weight loss — roughly twice the efficacy of liraglutide at comparable timepoints.
The STEP 8 trial, a head-to-head comparison of once-weekly semaglutide 2.4 mg versus once-daily liraglutide 3.0 mg, demonstrated that semaglutide resulted in significantly greater weight loss at 68 weeks (-15.8% vs -6.4%, difference -9.4 percentage points; 95% CI, -12.0 to -6.8; P<.001)[^2]. Participants had significantly greater odds of achieving ≥10%, ≥15%, and ≥20% weight loss with semaglutide versus liraglutide (odds ratios of 6.3, 7.9, and 8.2, respectively; all P<.001)[^2].
Side Effects
Common (≥5%)
- Nausea (39%) — most common, typically peaks in first 4–8 weeks
- Diarrhea (21%)
- Constipation (19%)
- Vomiting (16%)
- Headache (14%)
- Hypoglycemia (in combination with insulin/sulfonylureas)
Serious (Rare)
- Pancreatitis — discontinue if suspected
- Gallbladder disease — rapid weight loss increases risk
- Thyroid C-cell tumors — boxed warning (rodent data; avoid if personal/family history of MTC or MEN2)
- Heart rate increase — mean increase of 2–3 bpm; monitor in patients with cardiac conditions
Who Is a Candidate for Saxenda?
Adults with:
- BMI ≥30 (obesity), OR
- BMI ≥27 (overweight) + at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes)
Also FDA-approved for adolescents 12–17 with initial body weight >60 kg and BMI at or above the 95th percentile.
Liraglutide vs Semaglutide
| Feature | Liraglutide (Saxenda) | Semaglutide (Wegovy) |
|---|---|---|
| Dosing frequency | Daily | Weekly |
| Average weight loss | ~8% | ~15% |
| FDA-approved age | 12+ | 12+ |
| Cardiovascular benefit | ✓ (LEADER trial) | ✓ (SELECT trial) |
| Availability | Good | Variable (shortages) |
| Cost (list price) | ~$1,400/month | ~$1,349/month |
The pharmacokinetic differences between these agents explain their dosing schedules: liraglutide's half-life of 13-15 hours necessitates daily administration, while semaglutide's 165-hour half-life enables weekly dosing[^2]. Additionally, semaglutide exhibits approximately 3-fold greater potency at GLP-1 receptors than liraglutide, contributing to its superior efficacy[^3].
Cost and Insurance
- List price: ~$1,400/month (Saxenda)
- Insurance coverage varies — often requires documented weight loss attempts and comorbidities
- Novo Nordisk patient assistance program available for eligible patients
Conclusion
Liraglutide was a landmark medication that validated GLP-1 therapy for weight management. While newer agents like semaglutide offer greater efficacy with the convenience of weekly dosing, liraglutide remains a valid option when:
- Newer agents are unavailable due to shortages
- Insurance covers Saxenda but not Wegovy
- Daily injection is preferred over weekly (some patients prefer smaller doses)
- Established long-term cardiovascular safety data is important to the patient
Always consult your healthcare provider to determine whether liraglutide is the right choice for your individual situation.
References
[^1]: Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. DOI: 10.1002/osp4.84
[^2]: Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. DOI: 10.1001/jama.2021.23619
[^3]: Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. DOI: 10.3389/fendo.2019.00155
[^4]: Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. DOI: 10.1056/NEJMoa1411892
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.